生物活性分子抑制剂Daratumumab(Synonyms: 达雷木单抗; Anti-Human CD38, Human Antibody)

发表于由

生物活性分子抑制剂 特异性抑制剂 激动剂 化合物库 重组蛋白 Daratumumab (Synonyms: 达雷木单抗; Anti-Human CD38, Human Antibody) 纯度: 98.70%

Daratumumab (Anti-Human CD38) 是首创的特异性抗 CD38 单克隆抗体 (IgG1)。Daratumumab 具有抗多发性骨髓瘤(MM) 的作用。Daratumumab 损伤了 MM 细胞的粘附，从而增加了 MM 对蛋白酶体抑制的敏感性。

Daratumumab(Synonyms: 达雷木单抗; Anti-Human CD38, Human Antibody)

Daratumumab Chemical Structure

CAS No. : 945721-28-8

规格 价格 是否有货 数量
1 mg ￥1600 In-stock
5 mg ￥5600 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

生物活性

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition[1][2].

体外研究
(In Vitro)

Daratumumab (Anti-Human CD38) induces potent Ab-dependent cellular cytotoxicity in CD38-expressing lymphoma- and MM-derived cell lines[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Daratumumab (i.p.; 0.5 mg/kg; 14 d after challenge with Daudi-luc cells) inhibits outgrowth of CD38-expressing tumor cells in mouse xenograft tumor models[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 8- to 10-wk-old C.B-17 SCID mice (luciferase-expressing Daudi cells)[2]
Dosage: 0.5 mg/kg
Administration: I.p.; 14 day after challenge with Daudi-luc cells
Result: Effectively inhibited tumor growth compared with control-treated animals in which tumor grew rapidly and therefore required euthanasia on day 35. On day 28 and day 35, tumor size in Daratumumab-treated animals was significantly different from the control.

Clinical Trial

CAS 号

945721-28-8
中文名称

达雷妥尤单抗； 达妥木单抗
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7(10):e1486948. Published 2018 Jul 23.

    [2]. de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840-1848.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务